Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2025-08 - Roxadustat

Techniker Krankenkasse·Hamburg, Germany·Deadline Mar 30, 2027 · 216 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-08 - Roxadustat

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

Contract ends automatically at the end of the month when patent/market exclusivity expires, which could happen earlier...

No estimated value or guaranteed volume; revenue dependent on actual uptake.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclusion of rebate contracts under § 130c SGB V for the active ingredient Roxadustat.
  • Uniform contractual conditions, no individual negotiations.
Afficher le résumé complet

Open House procedure for discount agreements on the active ingredient Roxadustat under German law (SGB V). Techniker Krankenkasse (lead buyer) and Handelskrankenkasse (non-lead) intend to conclude non-exclusive rebate contracts with all eligible pharmaceutical entrepreneurs. One lot, no estimated value provided. The procedure allows joining at any time during the contract term (max. 24 months). Submission is not via eProcurement but by email or post. The contract ends automatically upon patent expiry. No analyzed procurement documents beyond the notice.

Risques

Contract ends automatically at the end of the month when patent/market exclusivity expires, which could happen earlier...

No estimated value or guaranteed volume; revenue dependent on actual uptake.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per § 4(18) AMG with a valid marketing authorization for the drug.
  • Must have registered office in Germany, EU, or EEA.

Eligibility

  • Must declare no exclusion grounds under §§ 123, 124 GWB (criminal convictions, etc.).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-08 - Roxadustat

Discount agreement for Roxadustat with uniform conditions; no exclusivity; maximum term from 01.04.2025 to 31.03.2027; early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Mar 2025 - Mar 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 30, 2027

Détails de la procédure

Date de publication
05 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
147964-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3